Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

A Factor VIII Fusion with an Inactivated FIX Generates a Biologically Active Molecule with Delayed Clearance in a FVIII/VWF Knockout Mouse Model

Oladipo Jude Akinwale, MSc,BSc, Ian Wilkinson, PhD, Christine Hough, PhD, David Lillicrap, MD FRCPC, Michael Makris, MD, Richard Ross, MD FRCP

Blood (2017) 130 (Supplement 1): 2344.

https://doi.org/10.1182/blood.V130.Suppl_1.2344.2344

Published: 2017

Journal Articles

A Novel Von Willebrand Factor Fragment Acts As a Chaperone to Prolong the Half-Life of Recombinant Human FVIII (Simoctocog Alfa) in Hemophilia a Dogs and FVIII/VWF Double Knockout Mice

Barbara A Solecka-Witulska, PhD, David Lillicrap, MD FRCPC, Christine Hough, PhD, Christoph Kannicht, PhD

Blood (2017) 130 (Supplement 1): 178.

https://doi.org/10.1182/blood.V130.Suppl_1.178.178

Published: 2017

Journal Articles

Biological considerations of plasma-derived and recombinant factor VIII immunogenicity

Jesse Lai, Christine Hough, Julie Tarrant, David Lillicrap

Blood (2017) 129 (24): 3147–3154.

https://doi.org/10.1182/blood-2016-11-750885

Published: 2017

Journal Articles

Development of an Optimized rAAV2/6 Human Factor 8 cDNA Vector Cassette for Hemophilia a Gene Therapy

Blood (2016) 128 (22): 1173.

https://doi.org/10.1182/blood.V128.22.1173.1173

Published: 2016

Journal Articles

Differential Glycosylation Between Recombinant Factor VIII Produced in Baby Hamster Kidney and Chinese Hamster Ovary Cells Confers Differences in Immunogenicity in a Humanized Hemophilia Α Mouse Model

Jesse Lai, BSc, Laura L Swystun, PhD, Dominique Cartier, Cunjie Zhang, MSc, Kate Nesbitt, James Dennis, PhD, Christine Hough, PhD, David Lillicrap, MD

Blood (2016) 128 (22): 326.

https://doi.org/10.1182/blood.V128.22.326.326

Published: 2016

Journal Articles

Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A

Jesse D. Lai, Paul C. Moorehead, Kate Sponagle, Katharina N. Steinitz, Birgit M. Reipert, Christine Hough, David Lillicrap

Blood (2016) 127 (26): 3439–3449.

https://doi.org/10.1182/blood-2015-11-679282

Published: 2016

Includes: Supplemental data

Journal Articles

Immunization Against Influenza but Not MMR Modulates the Anti-Factor VIII Immune Response in Hemophilia Α Mice

Jesse Lai, BSc, Paul C. Moorehead, MDMS, MSc, Kate Sponagle, Katharina Nora Steinitz, PhD, Birgit M Reipert, PhD, Christine Hough, PhD, David Lillicrap, MD

Blood (2014) 124 (21): 1501.

https://doi.org/10.1182/blood.V124.21.1501.1501

Published: 2014

Journal Articles

Administration of Dexamethasone during Initial Exposure to Factor VIII Induces Durable and Antigen-Specific Tolerance to Factor VIII in Hemophilia Α Mice with a Humanized Major Histocompatibility Complex II Transgene

Paul C. Moorehead, MDMS, MSc, Maria T. Georgescu, BScH, Alice S. van Velzen, MD, Kate Sponagle, Barbara Vidal, MSc, Birgit M. Reipert, PhD, Katharina Nora Steinitz, PhD, Christine Hough, PhD, David Lillicrap, MD

Blood (2014) 124 (21): 1489.

https://doi.org/10.1182/blood.V124.21.1489.1489

Published: 2014

Journal Articles

Administration of Dexamethasone during Initial Exposure to Factor VIII Prevents the Development of Anti-Factor VIII Antibodies and Increases the Proportion of Thymic but Not Splenic Regulatory T Cells in the Exon 16 Knockout C57Bl6 Hemophilia Α Mouse Model

Maria T. Georgescu, BScH, Paul C. Moorehead, MDMS, MSc, Kate Sponagle, Birgit M. Reipert, PhD, Christine Hough, PhD, David Lillicrap, MD

Blood (2014) 124 (21): 237.

https://doi.org/10.1182/blood.V124.21.237.237

Published: 2014

Journal Articles

Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response

Margareth C. Ozelo, Barbara Vidal, Christine Brown, Colleen Notley, Carol Hegadorn, Sandra Webster, Lori Harpell, James Ahlin, Andrew Winterborn, Janine Handforth, Valder R. Arruda, Christine Hough, David Lillicrap

Blood (2014) 123 (26): 4045–4053.

https://doi.org/10.1182/blood-2013-12-545780

Published: 2014

Includes: Supplemental data

Journal Articles

Myeloid-Derived Suppressor Cell (MDSC) Dynamics In FVIII-Exposed Hemophilia A Mice: Novel Therapeutic Implications

Brooke Snetsinger, MSc, Caroline Lin, BSc, Willy Weng, BSc, Alyssa Cull, MSc, Kate Sponagle, Christine Hough, PhD, David Lillicrap, Michael J. Rauh, MD, PhD

Blood (2013) 122 (21): 3569.

https://doi.org/10.1182/blood.V122.21.3569.3569

Published: 2013

Journal Articles

Platelet-Mediated Mechanical Tensile Force Influences ADAMTS13 Localization and Regulation Of Thrombus Development At The Site Of Platelet Accumulation

Yasuaki Shida, MD, PhD, Laura L. Swystun, PhD, Christine Brown, Jeff Mewburn, Kate Sponagle, Ozge Danisment, Jacob Riches, Christine Hough, PhD, David Lillicrap

Blood (2013) 122 (21): 454.

https://doi.org/10.1182/blood.V122.21.454.454

Published: 2013

Journal Articles

Immune-Modulatory Effects of Mesenchymal Stromal Cell Infusions for the Treatment of Factor VIII Inhibitor in Hemophilia A.

Hideto Matsui, MD, PhD, Lori Harpell, Sandra Powell, Moutih Rafei, PhD, Jacques Galipeau, MD, Christine Hough, PhD, David Lillicrap, MD

Blood (2009) 114 (22): 1299.

https://doi.org/10.1182/blood.V114.22.1299.1299

Published: 2009

Journal Articles

Genetically-Engineered Endothelial Cells Implanted Into the Omentum of Hemophilia A Dogs Provides Long-Term Circulating FVIII Resulting From Sustained FVIII Expression and Persistent Cell Viability.

Margareth C Ozelo, M.D., Ph.D., Hideto Matsui, MD, PhD, Carol A. Hegadorn, Lori Harpell, Sandra Powell, James F Hulvat, Ph.D., Andrew Winterborn, DVM, DACLAM, Janine Handforth, BSc, (Hons., Biol), DVM, Christine Hough, PhD, David Lillicrap, MD

Blood (2009) 114 (22): 3578.

https://doi.org/10.1182/blood.V114.22.3578.3578

Published: 2009

Journal Articles

Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice

Mohammad Qadura, Braden Waters, Erin Burnett, Rouzbeh Chegeni, Scott Bradshaw, Christine Hough, Maha Othman, David Lillicrap

Blood (2009) 114 (4): 871–880.

https://doi.org/10.1182/blood-2008-09-174649

Published: 2009

Includes: Supplemental data

Journal Articles

A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3 + T regulatory cells

Hideto Matsui, Masaru Shibata, Brian Brown, Andrea Labelle, Carol Hegadorn, Chandler Andrews, Marinee Chuah, Thierry VandenDriessche, Carol H. Miao, Christine Hough, David Lillicrap

Blood (2009) 114 (3): 677–685.

https://doi.org/10.1182/blood-2009-03-202267

Published: 2009

Journal Articles

Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4 + CD25 + -dependent mechanism and by shifting cytokine production to favor a Th1 response

Braden Waters, Mohammad Qadura, Erin Burnett, Rouzbeh Chegeni, Andrea Labelle, Patrick Thompson, Christine Hough, David Lillicrap

Blood (2009) 113 (1): 193–203.

https://doi.org/10.1182/blood-2008-04-151597

Published: 2009

Includes: Supplemental data

Journal Articles

Long-Term Phenotypic Correction of Hemophilia A Mice Following Intravenous Injection of miRNA-Regulated Lentiviral Vectors.

Hideto Matsui, MD, PhD, Margareth Ozelo, MD/PhD, Carol Hegadorn, Andrea Labelle, Erin Burnett, Angie Tuttle, Brian Brown, PhD, Luigi Naldini, MD/PhD, Christine Hough, PhD, David Lillicrap, MD

Blood (2007) 110 (11): 2587.

https://doi.org/10.1182/blood.V110.11.2587.2587

Published: 2007

Journal Articles

Ex Vivo Gene Trasfer for Hemophilia A That Enhances Safety and Results in Sustained In Vivo Factor VIII Expression from Lentivirally-Engineered Endothelial Progenitors.

Hideto Matsui, MD, PhD, Masaru Shibata, MD/PhD, Brian Brown, PhD, Andrea Labelle, Carol Hegadorn, Chandler Andrews, Robert P. Hebbel, MD, Jacques Galipeau, MD, Christine Hough, PhD, David Lillicrap, MD

Blood (2006) 108 (11): 3251.

https://doi.org/10.1182/blood.V108.11.3251.3251

Published: 2006

Journal Articles

Reduction in Factor VIII Inhibitors Mediated through Tolerogenic Antigen Presentation by immature Dendritic Cells.

Mohammad Qadura, BSc, Andrea Labelle, Kirsten Walker, Kathleen Pratt, PhD, Maha Othman, MD, PhD, Christine Hough, PhD, David Lillicrap, MD

Blood (2006) 108 (11): 762.

https://doi.org/10.1182/blood.V108.11.762.762

Published: 2006

NARROW

A Factor VIII Fusion with an Inactivated FIX Generates a Biologically Active Molecule with Delayed Clearance in a FVIII/VWF Knockout Mouse Model

A Novel Von Willebrand Factor Fragment Acts As a Chaperone to Prolong the Half-Life of Recombinant Human FVIII (Simoctocog Alfa) in Hemophilia a Dogs and FVIII/VWF Double Knockout Mice

Biological considerations of plasma-derived and recombinant factor VIII immunogenicity

Development of an Optimized rAAV2/6 Human Factor 8 cDNA Vector Cassette for Hemophilia a Gene Therapy

Differential Glycosylation Between Recombinant Factor VIII Produced in Baby Hamster Kidney and Chinese Hamster Ovary Cells Confers Differences in Immunogenicity in a Humanized Hemophilia Α Mouse Model

Concurrent influenza vaccination reduces anti-FVIII antibody responses in murine hemophilia A

Immunization Against Influenza but Not MMR Modulates the Anti-Factor VIII Immune Response in Hemophilia Α Mice

Administration of Dexamethasone during Initial Exposure to Factor VIII Induces Durable and Antigen-Specific Tolerance to Factor VIII in Hemophilia Α Mice with a Humanized Major Histocompatibility Complex II Transgene

Administration of Dexamethasone during Initial Exposure to Factor VIII Prevents the Development of Anti-Factor VIII Antibodies and Increases the Proportion of Thymic but Not Splenic Regulatory T Cells in the Exon 16 Knockout C57Bl6 Hemophilia Α Mouse Model

Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response

Myeloid-Derived Suppressor Cell (MDSC) Dynamics In FVIII-Exposed Hemophilia A Mice: Novel Therapeutic Implications

Platelet-Mediated Mechanical Tensile Force Influences ADAMTS13 Localization and Regulation Of Thrombus Development At The Site Of Platelet Accumulation

Immune-Modulatory Effects of Mesenchymal Stromal Cell Infusions for the Treatment of Factor VIII Inhibitor in Hemophilia A.

Genetically-Engineered Endothelial Cells Implanted Into the Omentum of Hemophilia A Dogs Provides Long-Term Circulating FVIII Resulting From Sustained FVIII Expression and Persistent Cell Viability.

Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice

A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3 + T regulatory cells

Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4 + CD25 + -dependent mechanism and by shifting cytokine production to favor a Th1 response

Long-Term Phenotypic Correction of Hemophilia A Mice Following Intravenous Injection of miRNA-Regulated Lentiviral Vectors.

Ex Vivo Gene Trasfer for Hemophilia A That Enhances Safety and Results in Sustained In Vivo Factor VIII Expression from Lentivirally-Engineered Endothelial Progenitors.

Reduction in Factor VIII Inhibitors Mediated through Tolerogenic Antigen Presentation by immature Dendritic Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only